Global Bloodstream Infection Testing Market 2018-2022
About Bloodstream Infection Testing
BSIs occur when any causative organism enters the bloodstream through a wound, injection, or during a surgical procedure. BSI testing is done to detect the cause of these infections.
Technavio’s analysts forecast the global bloodstream infection testing market to grow at a CAGR of 7.11% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global bloodstream infection testing market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Bloodstream Infection Testing Market 2018-2022
Technavio recognizes the following companies as the key players in the global bloodstream infection testing market: Abbott, BD, bioMérieux, Danaher, F. Hoffmann-La Roche, and Thermo Fisher Scientific.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is increased adoption of automation in healthcare. The healthcare industry is steadily adopting automated solutions to reduce the cost incurred on staffing and to generate accurate results. Also, automated solutions aid healthcare professionals in reducing the time taken for manually intensive tasks.”
According to the report, one driver in the market is increasing hospital visits. Hospitals are extremely responsible for spreading infections and increasing the rise in morbidity and mortality in hospitalized patients. The exposure of intensive care units to multiple invasive, therapeutic, and diagnostic procedures, increases the risk of spreading infections.
Further, the report states that one challenge in the market is high cost of instruments. The automated BSI testing products such as blood culture test instruments and equipment are generally expensive. The real-time PCR instruments are more expensive than other instruments.
F. Hoffmann-La Roche
Thermo Fisher Scientific